Uganda plans survey to determine prevalence of MDR-TB, health official says

Uganda this year plans to conduct a survey to determine the prevalence of multi-drug resistant tuberculosis in the country, National Leprosy and TB program manager Francis Adatu said Wednesday, the Monitor reports.

According to Adatu, the survey would "quantify the actual burden" and "determine the distribution" of MDR-TB in the country. Uganda will use the survey's findings to develop a national plan to address MDR-TB. According to Adatu, although MDR-TB is present in Uganda, its extent is unknown. A recent survey conducted at Arua Regional Hospital in Uganda's West Nile region found a 2.2% prevalence of MDR-TB, and a 1997 survey by the German Leprosy and TB Relief Association in southwest Uganda found a 1.1% prevalence of the disease.

In addition, Uganda plans to procure 100 courses of second-line TB drugs, Adatu said. He added that "early diagnosis" and effective drugs "properly used throughout the treatment period" could help curb the spread of MDR-TB. According to the Monitor, treatment for drug-sensitive TB costs about $30 over eight months, while treatment for MDR-TB costs about $1,500 over two years (Kirunda, Monitor, 9/12).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quabodepistat combo shows promise for safer, faster tuberculosis treatment